|1.||Bordignon, Claudio: 6 articles (12/2011 - 01/2010)|
|2.||Lambiase, Antonio: 6 articles (12/2011 - 01/2010)|
|3.||Bordignon, C: 5 articles (01/2013 - 07/2009)|
|4.||Lambiase, A: 5 articles (01/2013 - 07/2009)|
|5.||Gregorc, Vanesa: 4 articles (12/2013 - 01/2010)|
|6.||Rossoni, Gilda: 4 articles (12/2013 - 01/2010)|
|7.||Citterio, Giovanni: 4 articles (04/2011 - 01/2010)|
|8.||Caligaris-Cappio, Federico: 4 articles (04/2011 - 01/2010)|
|9.||Santoro, A: 3 articles (01/2013 - 07/2009)|
|10.||Citterio, G: 3 articles (06/2012 - 07/2009)|
12/01/2011 - "In a phase I study NGR-hTNF, DCE-MRI was performed at baseline and 2 h after NGR-hTNF administration in 31 patients with advanced solid cancer. "
02/15/2010 - "This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors. "
02/15/2010 - "Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041)."
12/01/2011 - "Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients."
02/15/2010 - "DCE-MRI results of tumors showed a vascular response to NGR-hTNF. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
10/01/2010 - "Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy."
10/01/2010 - "We evaluated the activity and safety of low-dose NGR-hTNF in colorectal cancer (CRC) patients failing standard therapies. "
04/01/2011 - "Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies."
04/01/2011 - "Two sequential cohorts of 12 colorectal cancer (CRC) patients who had failed standard therapies received NGR-hTNF 0.8 or 45 μg/m(2) in combination with capecitabine-oxaliplatin (XELOX). "
|3.||Ovarian Neoplasms (Ovarian Cancer)
09/07/2010 - "NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. "
01/01/2010 - "NGR-hTNF consists of human tumour necrosis factor-alpha (hTNF-alpha) fused to the tumour-homing peptide NGR, a ligand of an aminopeptidase N/CD13 isoform, which is overexpressed on endothelial cells of newly formed tumour blood vessels. "
10/01/2010 - "NGR-hTNF consists of human tumour necrosis factor (hTNF) fused with the tumour-homing peptide Asp-Gly-Arg (NGR), which is able to selectively bind an aminopeptidase N overexpressed on tumour blood vessels. "
01/15/2013 - "NGR-hTNF exploits the peptide asparagine-glycine-arginine (NGR) for selectively targeting tumour necrosis factor (TNF) to CD13-overexpressing tumour vessels. "
04/01/2011 - "asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the tumour vasculature, showed a biphasic dose-response curve in preclinical models. "
|5.||Neoplasm Metastasis (Metastasis)
|3.||CD13 Antigens (Alanine Aminopeptidase)
|4.||Glycine (Aminoacetic Acid)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)